The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Key issues in induction therapy for transplant-eligible and transplant-ineligible multiple myeloma
Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares the key points discussed at the session on induction therapy for newly diagnosed multiple myeloma that was held at this year’s IMS meeting. In this session, experts discussed intensifying induction and maintenance therapy in transplant-eligible patients as well as the impact of frailty on treatment delivery and outcomes in transplant-ineligible patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
